AP2000001963A0 - Paroxetine ascorbate. - Google Patents
Paroxetine ascorbate.Info
- Publication number
- AP2000001963A0 AP2000001963A0 APAP/P/2000/001963A AP2000001963A AP2000001963A0 AP 2000001963 A0 AP2000001963 A0 AP 2000001963A0 AP 2000001963 A AP2000001963 A AP 2000001963A AP 2000001963 A0 AP2000001963 A0 AP 2000001963A0
- Authority
- AP
- ARIPO
- Prior art keywords
- paroxetine ascorbate
- paroxetine
- ascorbate
- useful
- treatment
- Prior art date
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title abstract 4
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 title abstract 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title abstract 2
- 229940072107 ascorbate Drugs 0.000 title abstract 2
- 235000010323 ascorbic acid Nutrition 0.000 title abstract 2
- 239000011668 ascorbic acid Substances 0.000 title abstract 2
- 229960002296 paroxetine Drugs 0.000 title abstract 2
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Paroxetine ascorbate is useful in the treatment of certain CNS disorders
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9808896.6A GB9808896D0 (en) | 1998-04-25 | 1998-04-25 | Novel compound |
| PCT/GB1999/001244 WO1999055698A1 (en) | 1998-04-25 | 1999-04-23 | Paroxetine ascorbate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2000001963A0 true AP2000001963A0 (en) | 2000-12-31 |
Family
ID=10831008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/2000/001963A AP2000001963A0 (en) | 1998-04-25 | 1999-04-23 | Paroxetine ascorbate. |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1089995A1 (en) |
| JP (1) | JP2002513019A (en) |
| KR (1) | KR20010042977A (en) |
| CN (1) | CN1297448A (en) |
| AP (1) | AP2000001963A0 (en) |
| AU (1) | AU3618499A (en) |
| BG (1) | BG104940A (en) |
| BR (1) | BR9909868A (en) |
| CA (1) | CA2330055A1 (en) |
| EA (1) | EA200001104A1 (en) |
| GB (1) | GB9808896D0 (en) |
| HU (1) | HUP0102116A3 (en) |
| ID (2) | ID26083A (en) |
| IL (1) | IL139081A0 (en) |
| NO (1) | NO20005352L (en) |
| PL (1) | PL343677A1 (en) |
| SK (1) | SK15912000A3 (en) |
| TR (1) | TR200003084T2 (en) |
| WO (1) | WO1999055698A1 (en) |
| ZA (1) | ZA200005912B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003232D0 (en) * | 2000-02-11 | 2000-04-05 | Smithkline Beecham Plc | Novel composition |
| IL159280A0 (en) * | 2001-06-14 | 2004-06-01 | Teva Pharma | A process for preparing paroxetine hcl which limits formation of pink colored compounds |
| EP1469827B1 (en) * | 2002-01-09 | 2017-12-27 | Emisphere Technologies, Inc. | Polymorphs of sodium 4- (4-chloro-2-hydroxybenzoyl)amino butanoate |
| WO2020088481A1 (en) * | 2018-10-30 | 2020-05-07 | 中国科学院化学研究所 | Method for preparing drug or drug intermediate single crystal or amorphous substance |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| EP0223403B1 (en) * | 1985-10-25 | 1993-08-04 | Beecham Group Plc | Piperidine derivative, its preparation, and its use as medicament |
| US5276042A (en) * | 1993-04-16 | 1994-01-04 | Crenshaw Roger T | Treatment of premature ejaculation |
| ES2117557B1 (en) * | 1996-02-29 | 1999-07-01 | Ferrer Int | NEW PROCEDURE FOR OBTAINING (-) - TRANS -N-P-FLUOROBENZOILMETIL-4- (P-FLUOROFENIL) -3- ((3,4- (METHYLENDIOXI) PHENOXI) METHYL) -PIPERIDINE. |
-
1998
- 1998-04-25 GB GBGB9808896.6A patent/GB9808896D0/en not_active Ceased
-
1999
- 1999-04-23 BR BR9909868-7A patent/BR9909868A/en not_active Application Discontinuation
- 1999-04-23 KR KR1020007011809A patent/KR20010042977A/en not_active Withdrawn
- 1999-04-23 AP APAP/P/2000/001963A patent/AP2000001963A0/en unknown
- 1999-04-23 EP EP99918151A patent/EP1089995A1/en not_active Withdrawn
- 1999-04-23 CN CN99805160A patent/CN1297448A/en active Pending
- 1999-04-23 TR TR2000/03084T patent/TR200003084T2/en unknown
- 1999-04-23 SK SK1591-2000A patent/SK15912000A3/en unknown
- 1999-04-23 EA EA200001104A patent/EA200001104A1/en unknown
- 1999-04-23 ID IDW20002168A patent/ID26083A/en unknown
- 1999-04-23 HU HU0102116A patent/HUP0102116A3/en unknown
- 1999-04-23 CA CA002330055A patent/CA2330055A1/en not_active Abandoned
- 1999-04-23 JP JP2000545858A patent/JP2002513019A/en active Pending
- 1999-04-23 PL PL99343677A patent/PL343677A1/en not_active Application Discontinuation
- 1999-04-23 WO PCT/GB1999/001244 patent/WO1999055698A1/en not_active Ceased
- 1999-04-23 IL IL13908199A patent/IL139081A0/en unknown
- 1999-04-23 AU AU36184/99A patent/AU3618499A/en not_active Abandoned
- 1999-04-23 ID IDW20002169A patent/ID26654A/en unknown
-
2000
- 2000-10-23 ZA ZA200005912A patent/ZA200005912B/en unknown
- 2000-10-24 NO NO20005352A patent/NO20005352L/en not_active Application Discontinuation
- 2000-11-13 BG BG104940A patent/BG104940A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2330055A1 (en) | 1999-11-04 |
| HUP0102116A2 (en) | 2002-05-29 |
| CN1297448A (en) | 2001-05-30 |
| TR200003084T2 (en) | 2001-02-21 |
| ZA200005912B (en) | 2001-12-19 |
| SK15912000A3 (en) | 2001-04-09 |
| PL343677A1 (en) | 2001-08-27 |
| JP2002513019A (en) | 2002-05-08 |
| BR9909868A (en) | 2000-12-19 |
| KR20010042977A (en) | 2001-05-25 |
| AU3618499A (en) | 1999-11-16 |
| NO20005352D0 (en) | 2000-10-24 |
| WO1999055698A1 (en) | 1999-11-04 |
| HUP0102116A3 (en) | 2002-12-28 |
| EA200001104A1 (en) | 2001-04-23 |
| EP1089995A1 (en) | 2001-04-11 |
| BG104940A (en) | 2001-09-28 |
| GB9808896D0 (en) | 1998-06-24 |
| ID26654A (en) | 2001-01-25 |
| ID26083A (en) | 2000-11-23 |
| IL139081A0 (en) | 2001-11-25 |
| NO20005352L (en) | 2000-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9709915A (en) | Peptidyl heterocycles useful in the treatment of thrombin related disorders. | |
| NZ335981A (en) | Ketobenzamides as calpain inhibitors | |
| PL348817A1 (en) | Compositions and methods for the treatment of anorectal disorders | |
| ZA200107689B (en) | 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders. | |
| CY2431B1 (en) | Novel phenanthridines substituted in the 6 position. | |
| IL155589A0 (en) | Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders | |
| AU1742200A (en) | Prevention and treatment of amyloid-associated disorders | |
| YU48698A (en) | Carboxamide derivatives of pyrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorder | |
| EP0909561A3 (en) | Use of reboxetine for the treatment of attention-deficit/hyperactivity disorder | |
| ZA964762B (en) | Peptidyl heterocycles useful in the treatment of thrombin related disorders. | |
| ZA964761B (en) | Peptidyl heterocycles useful in the treatment of thrombin related disorders. | |
| CY2482B1 (en) | Paroxetine in treatment of depression. | |
| IL154051A0 (en) | 4-,5-,6-, and 7-indole derivatives useful for the treatment of cns disorders | |
| PL331882A1 (en) | Substituted 1,2,3,4-tetrahydro-2-dibenzofurane amines and 2-amino cyclohepta[b]benzofuranes | |
| AP2000001963A0 (en) | Paroxetine ascorbate. | |
| MXPA02011558A (en) | Novel mmp 2 mmp 9 inhibitors. | |
| SG148840A1 (en) | Indole derivatives useful for the treatment of cns disorders | |
| NO20001758D0 (en) | Methods and compositions for the treatment of arthritis | |
| IL128028A0 (en) | Treatment of psychotic disorders | |
| BG104914A (en) | Paroxetine maleate | |
| NZ511997A (en) | Isonipecotamides for the treatment of integrin-mediated disorders | |
| ZA991144B (en) | Treatment of iron chloride. | |
| AP2000001958A0 (en) | Paroxetine 10-camphorsulfornate for treatment of CNS disorders. | |
| IL152782A0 (en) | S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders | |
| EP1143998A4 (en) | Treatment of hypertension |